CCL22 and Alzheimer disease: Recent studies have demonstrated that baseline expression levels of the chemokine C-C motif ligand 22 (CCL22) at AD lesions serve as a reliable predictive biomarker for responses to topical crisaborole, cyclosporine, and fezakinumab.